Menu visibility control

Video

Events

Startup Surgery

Most Recent

Government & Policy

PM Theresa May to reveal Industrial Strategy Challenge Fund to support UK tech

Tech City Voices

Here’s how tech for good startups can maximise their chances of getting funded

Investments

Habito lands £5.5m in Series A round led by Silicon Valley’s Ribbit Capital

Press Releases

Starling Bank first of digital challengers to join Faster Payments as direct partner
No more electronic ‘loose change’: innovative fintech charity payment scheme launched today across 6,000 UK schools
Chimni calls for the UK proptech community to work more closely with the housebuilding industry

Oxford BioTherapeutics secures $10m from Silicon Valley Bank

Medical Lab
twitterlinkedinFacebookgoogle_plustwitterlinkedinFacebookgoogle_plus

Oxford BioTherapeutics has secured a $10m capital term loan from Silicon Valley Bank to accelerate the expansion of its research and development efforts.

OBT is an international clinical stage biotechnology company focused on developing innovative antibody based therapeutics, including antibody-drug conjugates, to treat cancer and other diseases.

OBT uses the optimal combination of technologies in ADC development through its collaborations with leading companies in the field and its novel OGAP target discovery system – one of the largest of its kind in the world – to provide a unique range of validated, novel antigen targets.

What Silicon Roundabout can learn from Silicon Alley

Christian Rohlff, CEO of Oxford BioTherapeutics, said: “This additional financial support will enable Oxford BioTherapeutics to accelerate the development of our medicines.

“With a long history of supporting life science businesses, Silicon Valley Bank is a valuable partner that recognises Oxford BioTherapeutics’ ability to transform the treatment of cancer and other diseases in an innovative way.”

Nooman Haque, director of UK life sciences and healthcare for Silicon Valley Bank, added: “Silicon Valley Bank is working alongside leading UK life science businesses, like Oxford BioTherapeutics, to provide financial solutions that support this sector’s ambitions to bring innovative therapies to the market.

“This financing demonstrates Silicon Valley Bank’s unique ability to work with businesses like Oxford BioTherapeutics by complementing their equity financing to provide an efficient solution to help stimulate their growth.”

The financing will provide $10m in capital, with $5m being funded immediately. The debt will complement new equity the company is raising.

Enter your e-mail address to receive updates straight to your inbox

* indicates required
Send me news on...
twitterlinkedinFacebookgoogle_plustwitterlinkedinFacebookgoogle_plus

Editor's picks

Theresa May

PM Theresa May to reveal Industrial Strategy Challenge Fund to support UK tech
posted 4 hours ago

Tech for good

Here’s how tech for good startups can maximise their chances of getting funded
posted 7 hours ago

habito

Habito lands £5.5m in Series A round led by Silicon Valley’s Ribbit Capital
posted 14 hours ago

BULB Amit Gudka

Amit Gudka, co-founder of Bulb, on the biggest misconceptions of startup life and his proudest moment so far
posted on January 22, 2017

Reports

Top tech stats: HealthTech investments trends, AI within business & more
posted on January 21, 2017

legal robot

AI and the legal sector: Opportunities, challenges and predictions
posted on January 20, 2017